Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.83 |
| ▸ | LMNA | P02545 | 2/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.83 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.83 |
| ▸ | PRKCG | P05129 | 1/20 | 0.83 |
| ▸ | PRKCB | P05771 | 1/20 | 0.83 |
| ▸ | PRKCA | P17252 | 1/20 | 0.83 |
| ▸ | PRKCH | P24723 | 1/20 | 0.83 |
| ▸ | PRKCI | P41743 | 1/20 | 0.83 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.83 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.83 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.83 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.83 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.83 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.83 |
| ▸ | MEN1 | O00255 | 1/20 | 0.83 |
| ▸ | GMNN | O75496 | 1/20 | 0.83 |
| ▸ | BLM | P54132 | 1/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10565337 | 1.00 | AKT1 (0.83) | AKT1LMNAALDH1A1PRKD3PRKCG | |
| SCHEMBL15477735 | 1.00 | AKT1 (0.83) | AKT1LMNAALDH1A1PRKD3PRKCG | |
| SCHEMBL10564175 | 1.00 | AKT1 (0.83) | AKT1LMNAALDH1A1PRKD3PRKCG | |
| SCHEMBL2582886 | 1.00 | AKT1 (0.83) | AKT1LMNAALDH1A1PRKD3PRKCG | |
| SCHEMBL1532761 | 1.00 | AKT1 (0.83) | AKT1LMNAALDH1A1PRKD3PRKCG | |
| SCHEMBL10565746 | 1.00 | AKT1 (0.83) | AKT1LMNAALDH1A1PRKD3PRKCG | |
| SCHEMBL417053 | 1.00 | AKT1 (0.83) | AKT1LMNAALDH1A1PRKD3PRKCG | |
| SCHEMBL10602960 | 1.00 | AKT1 (0.83) | AKT1LMNAALDH1A1PRKD3PRKCG | |
| SCHEMBL4320248 | 1.00 | AKT1 (0.83) | AKT1LMNAALDH1A1PRKD3PRKCG | |
| SCHEMBL2734265 | 1.00 | AKT1 (0.83) | AKT1LMNAALDH1A1PRKD3PRKCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070264206-A1 | Mucosal formulation | KIMBERLY-CLARK WORLDWIDE, INC. | 2007-11-15 | — | — | US | claimed |
| US-20260097150-A1 | Implantable Device for Treating an Ocular Condition | CELANESE EVA PERFORMANCE POLYMERS LLC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260096985-A1 | Injectable Composition For Drug Delivery | CELANESE EVA PERFORMANCE POLYMERS LLC | 2026-04-09 | — | — | US | disclosed |
| US-20260096984-A1 | Implantable Device for Administering a Therapeutic Agent | CELANESE EVA PERFORMANCE POLYMERS LLC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-18 | — | — | US | disclosed |
| EP-4312951-A1 | IMPLANTABLE MEDICAL DEVICE FOR THE DELIVERY OF NUCLEIC ACID-ENCAPSULATED PARTICLES | Celanese EVA Performance Polymers LLC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-11801227-B2 | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis | MODERNATX, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230330260-A1 | RNA FORMULATIONS | ModemaTX, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
| US-11786607-B2 | RNA formulations | MODERNATX, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230323371-A1 | POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | MODERNATX, INC. | 2023-10-12 | — | — | US | disclosed |
| WO-2017201328-A1 | POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201332-A1 | POLYNUCLEOTIDES ENCODING ACYL-COA DEHYDROGENASE, VERY LONG-CHAIN FOR THE TREATMENT OF VERY LONG-CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201346-A1 | POLYNUCLEOTIDES ENCODING PORPHOBILINOGEN DEAMINASE FOR THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201348-A1 | POLYNUCLEOTIDES ENCODING GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE FOR THE TREATMENT OF GALACTOSEMIA TYPE 1 | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201349-A1 | POLYNUCLEOTIDES ENCODING CITRIN FOR THE TREATMENT OF CITRULLINEMIA TYPE 2 | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201317-A1 | POLYRIBONUCLEOTIDES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| US-8703179-B2 | Mucosal formulation | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-7906147-B2 | superparamagnetic nanoparticles of iron coated with bilayer of molecules:(a) layer of oleic acid in direct contact with the iron particles; (b) a layer of Tween\"; bilayer of surface binding molecules and amphiphatic molecules; self-assembles; solubilizing; reducing toxicity; gold in MRI and tomography | NANOPROBES, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20080089836-A1 | superparamagnetic nanoparticles of iron coated with bilayer of molecules:(a) layer of oleic acid in direct contact with the iron particles; (b) a layer of Tween\"; bilayer of surface binding molecules and amphiphatic molecules; self-assembles; solubilizing; reducing toxicity; gold in MRI and tomography | NANOPROBES, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20070264206-A1 | Mucosal formulation | KIMBERLY-CLARK WORLDWIDE, INC. | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC47A1, TMEM205 | AKT1 3345/4885LMNA 2139/4885ALDH1A1 3662/4885 |
| US-20080089836-A1 | superparamagnetic nanoparticles of iron coated with bilayer of molecules:(a) layer of oleic acid in direct contact with the iron particles; (b) a layer of Tween\"; bilayer of surface binding molecules and amphiphatic molecules; self-assembles; solubilizing; reducing toxicity; gold in MRI and tomography | TFRC, FABP1, SCARB1 | AKT1 1049/4885LMNA 2687/4885ALDH1A1 4468/4885 |
| US-11786607-B2 | RNA formulations | SYNCRIP, NSUN3, RNMT | AKT1 3001/4885LMNA 700/4885ALDH1A1 4010/4885 |
| US-20230330260-A1 | RNA FORMULATIONS | SYNCRIP, NSUN3, RNMT | AKT1 3001/4885LMNA 700/4885ALDH1A1 4010/4885 |
| US-11801227-B2 | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis | CFTR, SLC47A1, TMEM205 | AKT1 3345/4885LMNA 2139/4885ALDH1A1 3662/4885 |
| US-20260097150-A1 | Implantable Device for Treating an Ocular Condition | P4HTM, ITGAM, TIMM44 | AKT1 2564/4885LMNA 3360/4885ALDH1A1 246/4885 |
| US-20230323371-A1 | POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | GBA1, GAA, GLA | AKT1 4381/4885LMNA 77/4885ALDH1A1 2985/4885 |
| US-20260096984-A1 | Implantable Device for Administering a Therapeutic Agent | GHITM, O60361, P4HTM | AKT1 1268/4885LMNA 3525/4885ALDH1A1 2350/4885 |
| US-20070264206-A1 | Mucosal formulation | MUC1, CHMP4B, VMA21 | AKT1 1224/4885LMNA 2111/4885ALDH1A1 4343/4885 |
| US-20260096985-A1 | Injectable Composition For Drug Delivery | SAMM50, OPRM1, IRAK4 | AKT1 1513/4885LMNA 3018/4885ALDH1A1 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.